Reference · Updated continuously
Aesthetics Stock & M&A Watch
The companies whose moves hit your margins, supply, and competition. Each is paired with why it matters to an owner and the latest filing that explains a move — never a bare number. Closes as of 2026-11-06.
+3.5%
Complex, avg move
16 / 6
Advancers / decliners
SKIN +51.79%
Top mover
STAA -5.65%
Biggest decliner
▲ Leading today 16 advancing
- 1 SKIN The Beauty Health Company (HydraFacial) +51.79%
- 2 HIMS Hims & Hers Health +8.06%
- 3 ELF e.l.f. Beauty +5.73%
- 4 ALGN Align Technology (Invisalign) +4.16%
- 5 VKTX Viking Therapeutics +4.07%
- 6 ESTA Establishment Labs +4.04%
- 7 COTY Coty +3.58%
- 8 BHC Bausch Health (Solta) +2.76%
- 9 EL Estée Lauder +2.24%
▼ Lagging today 6 declining
- 1 STAA STAAR Surgical -5.65%
- 2 APYX Apyx Medical (Renuvion) -4.25%
- 3 LRLCY L'Oréal (CeraVe · SkinCeuticals) -1.33%
- 4 LLY Eli Lilly -0.79%
- 5 ULTA Ulta Beauty -0.78%
- 6 INMD InMode Ltd. -0.52%
Previous close, % change. Hover any name for its detail.
| Ticker | % change |
|---|---|
| SKIN | +51.79% |
| HIMS | +8.06% |
| ELF | +5.73% |
| ALGN | +4.16% |
| VKTX | +4.07% |
| ESTA | +4.04% |
| COTY | +3.58% |
| BHC | +2.76% |
| EL | +2.24% |
| JNJ | +1.43% |
| ABBV | +1.07% |
| HSIC | +0.87% |
| EOLS | +0.15% |
| AMGN | +0.03% |
| NVO | +0.02% |
| SSKN | +0% |
| INMD | -0.52% |
| ULTA | -0.78% |
| LLY | -0.79% |
| LRLCY | -1.33% |
| APYX | -4.25% |
| STAA | -5.65% |
Injectables & Neurotoxins
069620.KSDaewoong Pharmaceutical (Nabota · Jeuveau)
private / foreign — via news
Makes Nabota/Jeuveau for Evolus; manufacturing capacity and supply news drives Jeuveau availability and pricing. [foreign]
086900.KQMedytox (Innotox)
private / foreign — via news
Liquid, ready-to-use toxin Innotox in US trials; a US approval adds a no-reconstitution competitor. [foreign]
145020.KQHugel (Letybo · Botulax)
private / foreign — via news
Korea's #1 toxin maker; Letybo won US FDA approval and is pushing hard into US medspas — a real Botox challenger on price. [foreign]
214450.KQPharma Research (Rejuran)
private / foreign — via news
Rejuran polynucleotide skin booster — one of the fastest-rising demand categories — plus a new toxin. [foreign]
243070.KQHuons BioPharma (Liztox)
private / foreign — via news
Emerging Korean toxin exporter with US ambitions. [foreign]
ABBVAbbVie (Allergan Aesthetics)
$291.31+1.07%
+34.5% 1y
Botox/Juvéderm + Allē loyalty — the bellwether; pricing/rebate moves hit every injector's margins.Latest filing: 2026-11-02T00:00:00+00:00 →
EOLSEvolus
$6.80+0.15%
-37.7% 1y
Jeuveau/'Newtox' + Evolus Rewards; markets aggressively to medspas — price wars start here.Latest filing: 2026-11-04T00:00:00+00:00 →
GALDGalderma Group
private / foreign — via news
Restylane/Sculptra/Dysport(US)/Alastin — huge footprint. Swiss-listed; IR/news only.
IPNIpsen
private / foreign — via news
Dysport originator. Foreign-listed; news/IR only.
MERZMerz Aesthetics
private / foreign — via news
Xeomin toxin, Radiesse and Belotero fillers, Ultherapy. Private — track product, approval, and pricing news. [private]
RVNCRevance Therapeutics
close pending
Daxxify (long-duration tox) + RHA fillers — the main Botox challenger; duration data shifts what owners stock.
SINCLAIRSinclair (Ellansé · MaiLi)
private / foreign — via news
Ellansé (PCL biostimulator) and MaiLi HA fillers. [private]
TEOXANETeoxane (RHA fillers)
private / foreign — via news
Maker of the RHA resilient-HA filler line (Revance distributes in the US). [private]
Energy Devices & Lasers
1696.HKSisram Medical (Alma Lasers)
private / foreign — via news
Parent of Alma Lasers (Harmony, Soprano) — a major aesthetic-laser maker. HK-listed; news/IR only.
APYXApyx Medical (Renuvion)
$2.93-4.25%
+89.4% 1y
Renuvion helium-plasma skin tightening and body contouring — a device-adoption and safety signal.Latest filing: 2026-11-05T00:00:00+00:00 →
BHCBausch Health (Solta)
$8.18+2.76%
-23.5% 1y
Solta: Thermage/Fraxel/Clear+Brilliant; watch for spin-off/M&A affecting support & pricing.Latest filing: 2026-10-28T00:00:00+00:00 →
BTLBTL Industries
private / foreign — via news
Emsculpt NEO and Emsella — among the most-marketed body and pelvic-floor devices in medspas. Private, but product news is essential. [private]
CANDELACandela Medical
private / foreign — via news
GentleMax, Nordlys, Profound RF, and Ellacor micro-coring (a hot new skin-removal modality). Private, PE-owned. [private]
CUTRCutera
close pending
Laser systems; financial distress/turnaround = discount/used-device signals for buyers.
CYNOSURECynosure (with Lutronic)
private / foreign — via news
SculpSure, PicoSure, Potenza; merged operations with Lutronic. Private, PE-owned. [private]
DYNTDynatronics
close pending
Physical-medicine and aesthetic product distribution; a small-cap supply read.
ELN.MIEl.En. S.p.A. (Deka)
private / foreign — via news
Italian laser group (Deka) supplying core laser technology across aesthetics. [foreign]
FOTONAFotona
private / foreign — via news
Fotona 4D and NightLase dual-wavelength laser systems. [private/foreign]
HOLXHologic
close pending
Holds aesthetic/wellness device lines (diVa, MonaLisa Touch via the Cynosure legacy); diffuse, surfaces on aesthetic news.
INMDInMode Ltd.
$13.33-0.52%
+11.3% 1y
Morpheus8/RF leader; device-market bellwether — earnings signal price wars on the $100K+ gear owners finance.
LUMENISLumenis
private / foreign — via news
Stellar M22 IPL and NuEra RF; taken private after delisting. [private]
LUTRONICLutronic
private / foreign — via news
Genius RF and LaseMD; Korean maker taken private. [private]
SKINThe Beauty Health Company (HydraFacial)
$15.71+51.79%
-47.2% 1y
HydraFacial — the facial franchise on countless medspa menus; its health signals facial-category demand and consumable/device support.Latest filing: 2026-11-05T00:00:00+00:00 →
SSKNSTRATA Skin Sciences
$0.00+0%
-100% 1y
Dermatology and aesthetic light devices (XTRAC, excimer) — a derm-device demand signal.Latest filing: 2026-02-11T00:00:00+00:00 →
VEROVenus Concept
close pending
Devices + a financial-health/M&A signal; distress here = consolidation cue.
Plastic Surgery & Implants
ESTAEstablishment Labs
$67.02+4.04%
+122.7% 1y
Motiva implants; US-approval milestones = surgeon-side news + market mover.Latest filing: 2026-10-29T00:00:00+00:00 →
GCAESTHETICSGC Aesthetics
private / foreign — via news
Breast and body implant maker. Private. [private]
JNJJohnson & Johnson (Mentor)
$276.22+1.43%
+54.6% 1y
Mentor implants; surface only on aesthetics-specific news, not general JNJ.Latest filing: 2026-10-13T00:00:00+00:00 →
SIENSientra
private / foreign — via news
Breast implants and miraDry; restructured with assets sold — confirm current status before relying on it. [distress/acquired]
STAASTAAR Surgical
$25.21-5.65%
+52.3% 1y
Implantable lenses — an elective self-pay surgical demand read adjacent to aesthetics.Latest filing: 2026-11-04T00:00:00+00:00 →
GLP-1 / Weight-Loss (demand driver)
AMGNAmgen (MariTide)
$460.42+0.03%
+24.3% 1y
MariTide is a monthly-dosed GLP-1 pipeline entrant — future competition and pricing pressure in the weight-loss category.Latest filing: 2026-11-03T00:00:00+00:00 →
HIMSHims & Hers Health
$26.00+8.06%
-34.8% 1y
Telehealth/compounded GLP-1 — competitor to and signal for the medspa GLP-1 market.Latest filing: 2026-10-07T00:00:00+00:00 →
LLYEli Lilly
$1354.00-0.79%
+52.8% 1y
Zepbound/Mounjaro; supply/pricing & compounding-rule changes reshape what medspas can offer.Latest filing: 2026-10-29T00:00:00+00:00 →
NVONovo Nordisk
$40.31+0.02%
-21.8% 1y
Wegovy/Ozempic; shortage status & compounding crackdowns = direct medspa revenue impact.
VKTXViking Therapeutics
$26.84+4.07%
+15.8% 1y
Next-gen GLP-1/dual-agonist pipeline (VK2735) — future weight-loss supply and competition for the cash-pay GLP-1 market.Latest filing: 2026-10-28T00:00:00+00:00 →
Consumer Demand Signal
ALGNAlign Technology (Invisalign)
$166.00+4.16%
-7.3% 1y
Invisalign — a clean read on consumer appetite for elective self-improvement spend, adjacent to aesthetics.Latest filing: 2026-11-06T00:00:00+00:00 →
COTYCoty
$4.05+3.58%
-47% 1y
Mass and prestige beauty conglomerate — a broad consumer beauty-spend proxy.Latest filing: 2026-11-04T00:00:00+00:00 →
ELEstée Lauder
$110.06+2.24%
-5.8% 1y
Prestige skincare (La Mer, Clinique, The Ordinary) — a premium aesthetic-spend barometer.Latest filing: 2026-11-04T00:00:00+00:00 →
ELFe.l.f. Beauty
$116.14+5.73%
-37.4% 1y
Consumer aesthetic-spend proxy — is discretionary beauty spend up or down?Latest filing: 2026-11-04T00:00:00+00:00 →
LRLCYL'Oréal (CeraVe · SkinCeuticals)
$100.37-1.33%
+3.7% 1y
Owns CeraVe, SkinCeuticals, La Roche-Posay — the cosmeceutical lines medspas sell at the front desk; a retail-attach signal.
ULTAUlta Beauty
$644.76-0.78%
-2.8% 1y
Beauty retail + in-store services; macro demand signal for aesthetic spend.Latest filing: 2026-08-27T00:00:00+00:00 →
Supply & Distribution
CAHCardinal Health
private / foreign — via news
Distribution and supply chain for GLP-1 and consumables; diffuse.Latest filing: 2026-11-05T00:00:00+00:00 →
HSICHenry Schein
$86.05+0.87%
+27.1% 1y
Distribution; supply/pricing signal for consumables.Latest filing: 2026-11-03T00:00:00+00:00 →
MCKMcKesson
private / foreign — via news
Pharma distribution including GLP-1 and some aesthetic supply chain; diffuse, surfaces on supply news.Latest filing: 2026-11-04T00:00:00+00:00 →
PDCOPatterson Companies
close pending
Distribution; secondary supply-cost signal.
We translate these moves for you.
When one of these names makes a move that touches your business, Inside MedSpa Pro tells you what it means and what to do — not just the number.
Get the free briefEnd-of-day prices reflect the previous trading close and are for general information only — not investment advice and not a recommendation to buy or sell any security. Inside MedSpa is a general, impersonal publication for medical-aesthetics business owners. It is not individualized business, financial, medical, or legal advice. Any market or company information is general in nature and not a recommendation.